Glutamate agents in the treatment of mental disorders
US10052318B2 · kind B2 · utility
0Cited by
17References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 15, 2014 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | May 15, 2034 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH10F39/8053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.